Alephoson Biopharmaceuticals Limited (AB) is a private, technology-based company focusing on research and development of innovative drug delivery technologies to fulfil unmet medical needs. By utilizing the destructive, and proprietary next generation Cell Penetration Protein Alternation Technology (CePPA), we are working to overcome the limitations of current treatments for serious ophthalmic diseases by developing a topical eye drop alternative to intravitreal (back-of-the eye) injection therapies. At AB, we understand the critical role vision plays in a patient’s quality of life, and we know the frustration that ophthalmologists face when they are unable to treat their patients successfully, and for patients and families for whom the burden of chronic treatment can be overwhelming. We are determined to develop new ocular therapies that help patients see their very best throughout their lives. Our management team and board of directors bring extensive experience discovering, evaluating, developing, and commercializing drugs. These novel therapies may include improvements to existing medicines or entirely new molecules.